1. Home
  2. FSHP vs VIGL Comparison

FSHP vs VIGL Comparison

Compare FSHP & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FSHP
  • VIGL
  • Stock Information
  • Founded
  • FSHP 2018
  • VIGL 2020
  • Country
  • FSHP United States
  • VIGL United States
  • Employees
  • FSHP N/A
  • VIGL N/A
  • Industry
  • FSHP
  • VIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • FSHP
  • VIGL Health Care
  • Exchange
  • FSHP NYSE
  • VIGL Nasdaq
  • Market Cap
  • FSHP 90.7M
  • VIGL 89.3M
  • IPO Year
  • FSHP 2024
  • VIGL 2022
  • Fundamental
  • Price
  • FSHP $10.23
  • VIGL $2.80
  • Analyst Decision
  • FSHP
  • VIGL Strong Buy
  • Analyst Count
  • FSHP 0
  • VIGL 5
  • Target Price
  • FSHP N/A
  • VIGL $21.00
  • AVG Volume (30 Days)
  • FSHP 7.2K
  • VIGL 2.7M
  • Earning Date
  • FSHP 01-01-0001
  • VIGL 03-25-2025
  • Dividend Yield
  • FSHP N/A
  • VIGL N/A
  • EPS Growth
  • FSHP N/A
  • VIGL N/A
  • EPS
  • FSHP 0.11
  • VIGL N/A
  • Revenue
  • FSHP N/A
  • VIGL N/A
  • Revenue This Year
  • FSHP N/A
  • VIGL N/A
  • Revenue Next Year
  • FSHP N/A
  • VIGL N/A
  • P/E Ratio
  • FSHP $90.07
  • VIGL N/A
  • Revenue Growth
  • FSHP N/A
  • VIGL N/A
  • 52 Week Low
  • FSHP $9.99
  • VIGL $1.49
  • 52 Week High
  • FSHP $10.25
  • VIGL $6.06
  • Technical
  • Relative Strength Index (RSI)
  • FSHP N/A
  • VIGL 71.42
  • Support Level
  • FSHP N/A
  • VIGL $2.54
  • Resistance Level
  • FSHP N/A
  • VIGL $2.88
  • Average True Range (ATR)
  • FSHP 0.00
  • VIGL 0.20
  • MACD
  • FSHP 0.00
  • VIGL 0.03
  • Stochastic Oscillator
  • FSHP 0.00
  • VIGL 89.73

About FSHP FLAG SHIP ACQUISITION CORPORATION

Flag Ship Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

Share on Social Networks: